Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

January 24, 2020

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

January 30, 2019

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

News Conference News ISET 2019

Chelation for CLI in Diabetic Patients Shows Potential in Small Series

January 29, 2019

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

News Conference News ISET 2019

Paclitaxel in PAD: What to Tell Patients While the Numbers Are Crunched

January 28, 2019

PAD in the Spotlight: Awareness, Treatment Remain Low Despite Many Years of Research

News Conference News ISET 2019

PAD in the Spotlight: Awareness, Treatment Remain Low Despite Many Years of Research

January 28, 2019

MIMICS-2 at 1 Year: 3-D Stent Meets Safety and Effectiveness Goals

News Conference News ISET 2018

MIMICS-2 at 1 Year: 3-D Stent Meets Safety and Effectiveness Goals

February 08, 2018

Positive 6-Month Outcomes Seen With Endovascular Therapy for Symptomatic PAD: LIBERTY 360

News Conference News ISET 2017

Positive 6-Month Outcomes Seen With Endovascular Therapy for Symptomatic PAD: LIBERTY 360

February 07, 2017

Underappreciated by Clinicians, Critical Limb Ischemia Has Dire Fallout for Patients

News Conference News ISET 2017

Underappreciated by Clinicians, Critical Limb Ischemia Has Dire Fallout for Patients

February 07, 2017

Routine Screening of ABI to Identify PAD: Despite Guidelines, One Expert Asks Why Not?

News Conference News ISET 2017

Routine Screening of ABI to Identify PAD: Despite Guidelines, One Expert Asks Why Not?

February 06, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.